diltiazem has been researched along with flecainide in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.90) | 18.2507 |
| 2000's | 14 (45.16) | 29.6817 |
| 2010's | 12 (38.71) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Aiyar, J; Auperin, DD; Chandy, KG; Grissmer, S; Gutman, GA; Hanson, DC; Karmilowicz, MJ; Mather, RJ; Nguyen, AN | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Al-Sabi, A; Daly, D; Dolly, JO; Herron, C; Hoefer, P; Kaza, SK; Kinsella, GK; Metais, C; Nolan, K; Pickering, M | 1 |
| Allen, LV; Erickson, MA | 1 |
| Bataller, M; Chorro, FJ; Cortina, J; Espí, J; Guerrero, J; López-Merino, V; Ruipérez, JA; Sánchez-Muñoz, JJ; Sanchis, J | 1 |
| Itoh, E; Suzuki, K; Tanabe, Y | 1 |
| Alboni, P; Bottoni, N; Brignole, M; Cappato, R; Fucà, G; Menozzi, C; Paparella, N; Tomasi, C | 1 |
| Freestone, B; Lip, GY | 2 |
| Lip, GY | 1 |
| Leung, TK; Nattel, S; Rivard, L; Schram, G; Shiroshita-Takeshita, A; Sinno, H | 1 |
| Globits, S; Hirschl, MM; Wollmann, C | 1 |
| Greenough, G; Kapoor, M | 1 |
| Andrews, LM; Koch, BCP; van der Nagel, BCH; van Domburg, B | 1 |
| Ganesan, AN; Lahiri, A; Martin, DK; Quah, J; Tiver, KD | 1 |
4 review(s) available for diltiazem and flecainide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Propafenone; Timolol; Verapamil | 2003 |
Atrial fibrillation (acute).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Propafenone; Verapamil | 2004 |
Atrial fibrillation (recent onset).
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Flecainide; Humans; Propafenone; Verapamil | 2005 |
1 trial(s) available for diltiazem and flecainide
| Article | Year |
|---|---|
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Diltiazem; Drug Therapy, Combination; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Patient Readmission; Propranolol; Self Administration; Self Care; Tachycardia, Paroxysmal; Tachycardia, Supraventricular; Treatment Outcome | 2001 |
26 other study(ies) available for diltiazem and flecainide
| Article | Year |
|---|---|
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Topics: 3T3 Cells; Animals; Base Sequence; Benzopyrans; Capsaicin; Cell Line; Cells, Cultured; Charybdotoxin; Cloning, Molecular; Cromakalim; Diltiazem; Diterpenes; Elapid Venoms; Flecainide; Ion Channel Gating; Mice; Molecular Sequence Data; Nifedipine; Oligodeoxyribonucleotides; Peptides; Potassium Channels; Pyrroles; Scorpion Venoms; Sotalol | 1994 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
A Rational Design of a Selective Inhibitor for Kv1.1 Channels Prevalent in Demyelinated Nerves That Improves Their Impaired Axonal Conduction.
Topics: Animals; Cell Line; Corpus Callosum; Demyelinating Diseases; Drug Design; Humans; Kv1.1 Potassium Channel; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Potassium Channel Blockers; Pyrroles | 2017 |
Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids.
Topics: Baclofen; Captopril; Chromatography, High Pressure Liquid; Diltiazem; Dipyridamole; Drug Compounding; Drug Stability; Drug Storage; Flecainide; Solutions; Temperature | 1996 |
Modifications in the evolution of the dominant frequency in ventricular fibrillation induced by amiodarone, diltiazem, and flecainide. An experimental study.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Diltiazem; Dogs; Electrocardiography; Flecainide; Fourier Analysis; Signal Processing, Computer-Assisted; Time Factors; Ventricular Fibrillation | 1996 |
A case of vasospastic angina presenting Brugada-type ECG abnormalities.
Topics: Acetylcholine; Aged; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiovascular Agents; Chest Pain; Coronary Angiography; Coronary Vasospasm; Diagnosis, Differential; Diltiazem; Electric Stimulation; Electrocardiography; Electrophysiology; Flecainide; Humans; Male; Syncope; Syndrome; Vasodilator Agents; Ventricular Fibrillation | 1999 |
The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Coronary Disease; Diltiazem; Dogs; Electric Stimulation; Flecainide; Models, Animal; Nadolol; Phenethylamines; Potassium Channel Blockers; Refractory Period, Electrophysiological; Sodium Channel Blockers; Sulfonamides; Vagus Nerve | 2007 |
A 2-year survey of treatment of acute atrial fibrillation in an ED.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Diltiazem; Emergency Service, Hospital; Female; Flecainide; Humans; Male; Middle Aged; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
A 42-year-old female with well-controlled atrial fibrillation and mild obstructive sleep apnea.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Diltiazem; Drug Therapy, Combination; Female; Flecainide; Humans; Polysomnography; Sleep Apnea, Obstructive | 2015 |
High-throughput quantification of ten antiarrhythmic drugs in human plasma using UPLC-MS/MS.
Topics: Anti-Arrhythmia Agents; Atenolol; Bisoprolol; Carvedilol; Chromatography, High Pressure Liquid; Diltiazem; Flecainide; High-Throughput Screening Assays; Humans; Lidocaine; Metoprolol; Propranolol; Reproducibility of Results; Sotalol; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Verapamil | 2019 |
Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Block; Diltiazem; Electrocardiography; Flecainide; Humans; Male; Middle Aged | 2023 |